Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177776 | 0.84 | ATR (0.35) | ATRBMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL10177966 | 0.83 | PRKD1 (0.32) | ATR | |
| SCHEMBL10177583 | 0.82 | ATR (0.41) | ATRMTORPIK3CA | |
| SCHEMBL10177923 | 0.78 | ATR (0.32) | ATR | |
| SCHEMBL10177919 | 0.78 | ATR (0.41) | ATRBMPR1AACVRL1ACVR1MTOR | |
| SCHEMBL10177872 | 0.76 | ATR (0.33) | ATRBMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL10177787 | 0.75 | ATR (0.41) | ATRMTORPIK3CA | |
| SCHEMBL10177738 | 0.75 | ATR (0.37) | ATRMTORPIK3CA | |
| SCHEMBL10178413 | 0.75 | ATR (0.56) | ATRBMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL10177887 | 0.74 | ATR (0.37) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | ATR 1/4885BMPR1B 4027/4885BMPR1A 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.